| 
Results for biopharmaceutical. Search took 0.06 seconds.
Treatment For Gaucher Disease From Protalix
in Straightfromthedoc, on July 4, 2009
...rebroside accumulate in the spleen, liver, lungs, bone marrow, and sometimes in the brain.
Now, a biopharmaceutical company focused on the development and commercialization of recombinant therapeuti...
Carl Icahn 将正式卷起新 Yahoo 收购风波
in Wangtam, on 2008-05-17
刚刚已经提及， 亿万富翁 Carl Icahn 上周谋得 Yahoo 董事席位，意欲发动代理权争夺战 。然后 Carl Icahn 在随后发给 Yahoo 的信中确认，他已经发动了旨在促成微软收购 Yahoo 的代理权争夺战。 Carl Icahn 已经提名了十位 Yahoo 董事候选人，希望用他们取代现有 Yahoo 董事会，以推动 Yahoo 接受微软每股 33 美元、总价值 475 亿美元的收购报价。 Carl Icahn 还在写给 Yahoo 董事会主席 Roy Bostock 的信中披露，他已经收购了 5900 万股 Yahoo 股票，并在寻求清除来自国美国联邦贸易委员会的反垄...
Entelos Signed Agreement with J&J Pharma R&D for Diabetes Study
in Daily Diabetic, on December 22, 2007
...A biopharmaceutical company utilizing sophisticated mathematical models of human biology to discover and develop new drugs that treat and cure diabetes among other conditions - Entelos - ha...
Tourtellotte Solutions Blazes Trail with New Release of Clinical Trial Supply Chain Simulator
in Supplychainer, on September 8, 2007
...rea:
Tourtellotte Solutions , provider of off-the-shelf and custom supply chain software for the biopharmaceutical, retail, and consumer goods industries, announced on Tuesday the release of its t...
BIO Investor Forum 2007
in The Biotech Weblog, on September 7, 2007
What: BIO Investor Forum 2007
When: October 9-11, 2007
Where: Palace Hotel, San Francisco
The BIO Investor Forum 2007 showcases leading public and private biotechnology companies, from small to mid-cap public growth companies. There will be workshops on the following themes:
Alzhe...
Thrombosis Drug Dabigatran on Phase III Clincial Trials
in The Biotech Weblog, on February 14, 2007
.... Doctors leading the study say that unlike warfarin, dabigatran, which is manufactured by German biopharmaceutical firm Boehringer Ingelheim , does not appear to be easily affected by the patient...
MediciNova Initiates Phase II Trial on Insomnia Pill
in The Biotech Weblog, on January 25, 2007
...
Biopharmaceutical company MediciNova, Inc. announced the initiation of a Phase II clinical study to determine the safety and efficacy of MN-305 for the treatment of insomnia.
MN-305 is a pote...
Novo Nordisk Discontinues R&D on Small Molecules for Oral Treatment of Diabetes
in The Biotech Weblog, on January 23, 2007
...
Denmark-based biopharmaceutical firm Novo Nordisk will cease all its R&D programs in small molecules for the oral treatment of diabetes and will focus instead on its protein-based pharm...
BayBio:IMPACT 2007
in The Biotech Weblog, on December 6, 2006
... Northern California on individual lives around the world.
To access to the landmark study on the biopharmaceutical industry, click here .
...
SAP Software Founder Dietmar Hopp Invests On Biotechnology
in The Biotech Weblog, on July 28, 2006
...s over the past four years.
Among the 14 companies Hopp has invested on are mainly Germany-based biopharmaceutical firms, focusing on cancer and diseases of the central nervous system . Among t...
Gaboxadol Shows Promise As Sleeping Pill
in The Biotech Weblog, on June 22, 2006
...ormation .
Gaboxadol is aan experimental sleeping pill being co-developed by Merck and Danish H. biopharmaceutical firm Lundbeck A/S . More details about the clinical study from Reuters .
...
Merck Ups Stake in Schering, Threatening Bayer's Takeover
in The Biotech Weblog, on June 13, 2006
... It seems that the $20 billion merger between German biopharmaceutical giants Bayer and Schering may not take place afterall. Read the news from Forbes , from Reuters and from AP (via Canada.c...
Novartis Bids for NeuTec, Expands Into Hospital Anti-Infectives
in The Biotech Weblog, on June 8, 2006
...
Novartis is hoping to strengthen its biopharmaceutical portfolio by offering to acquire British firm
NeuTec Pharma plc for $570 million, a 109% premium to the current share price.
Ne...
Merck Acquires GlycoFi and Abmaxis for $480 Million
in The Biotech Weblog, on May 10, 2006
...t has potential use in developing novel biotherapeutics. Abmaxis , on the other hand, is a private biopharmaceutical company which optimizes and humanizes antibodies for human therapeutics and diag...
Amgen Seeks Banning of Roche's Anemia Drug, Cera
in The Biotech Weblog, on April 12, 2006
... Biopharmaceutical giant Amgen has filed a claim with the US International Trade Commission requesting for a ban on imports of an experimental anemia drug called Cera , manufactured by Roc...
Booming Biotech Industry in the Asia Pacific
in The Biotech Weblog, on April 12, 2006
...ellectual property protections.
The region is poised to become the major hub in producing generic biopharmaceutical drugs, stem cell research, and bioinformatics and clinical data management. Just r...
Serono Seeks Acquisitions Or Merger Instead of Take-Over
in The Biotech Weblog, on April 11, 2006
...company Serono is launching a search for acquisitions or a merger instead.
In November, when biopharmaceutical giants were considering taking over the company , its shares soared. But following...
The Irritable Bowel Syndrome (IBS): A Market Analysis
in The Biotech Weblog, on March 2, 2006
...Note that the article was written by two representatives from the Dynogen Pharmaceuticals, Inc , a biopharmaceutical firm developing drugs for gastrointestinal disorders, including IBS.
...
Acologix Secures $24.3M in Series C Financing Round
in The Biotech Weblog, on December 22, 2005
...
Yesterday, Acologix Inc., a privately held biopharmaceutical company, announced that it has raised $25.3 million in Series C financing, bringing its total raised fund to over $72 million.
Mos...
Serono Hold Talks With Biopharmaceutical Giants For Potential Take-over
in The Biotech Weblog, on November 9, 2005
Third biggest biotech company Serono has held talks with four biopharma giants about a potential $15 billion takeover. Interested parties were: Novartis, GlaxoSmithKline, Sanofi- Aventis and Pfizer. Amgen bows out, Roger Perlmutter, vice-president of research and development saying
...
RNA Antagonist SPC2996 Receives FDA Approval For Phase I/II Trials
in The Biotech Weblog, on November 8, 2005
...
Santaris Pharma , a Danish biopharmaceutical company developing anti-caner drugs using RNA-interference technology, received US FDA approval for its international Phase I/II study of SPC2996 ...
Patenting Human Genes
in The Biotech Weblog, on October 17, 2005
...nts each."
Although the ethics and propriety of gene patenting is still up for debate , the biopharmaceutical companies stillclaim ownership as fast as discoveries are made. The Genetics and ...
Biotech Companies Announcing Public Offering of Common Stocks
in The Biotech Weblog, on September 19, 2005
...ed underwritten public offering of common stock amounting to 4,000,000 primary shares. Renovis is a biopharmaceutical company developing drugs to treat neurological diseases and disorders. The most ad...
Profos AG raises 5M in First Financing Round
in The Biotech Weblog, on August 25, 2005
...eria in food products, using phage-ligand technology, and (2) Endotoxin detection and removal in biopharmaceutical drugs using EndoTrap� Read the full press release here .
...
OSI and Eyetech Merge
in The Biotech Weblog, on August 23, 2005
... Inc. have entered into a definitive merger agreement whereby OSI has agreed to acquire Eyetech, a biopharmaceutical company that focuses on the development and commercialization of novel therapeutic...
Keryx Biopharmaceuticals' Common Stock Offering
in The Biotech Weblog, on July 18, 2005
...
Keryx Biopharmaceuticals, Inc. announced yesterday the pricing of its public offering of 5,030,000 shares of its common stock at an offering price of $14.05 per share. J.P. Morgan Securities I...
Procyon Acquires Bioxalis Medica Inc.
in The Biotech Weblog, on July 13, 2005
...announced last week the successful acquisition of Bioxalis Medica Inc. (Bioxalis), a Montreal-based biopharmaceutical company engaged in the research and development of targeted liposomes for cancer t...